Published in Circ Cardiovasc Genet on March 06, 2015
Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat Med (2017) 1.53
IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nat Commun (2016) 0.87
Molecular Characterization of the NLRC4 Expression in Relation to Interleukin-18 Levels. Circ Cardiovasc Genet (2015) 0.78
Constitutive Activation of the Nlrc4 Inflammasome Prevents Hepatic Fibrosis and Promotes Hepatic Regeneration after Partial Hepatectomy. Mediators Inflamm (2015) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet (2005) 14.30
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Universal definition of myocardial infarction. Circulation (2007) 11.69
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med (2008) 9.61
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Transcriptome and genome sequencing uncovers functional variation in humans. Nature (2013) 8.89
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med (2013) 8.13
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
A randomized trial of genotype-guided dosing of warfarin. N Engl J Med (2013) 7.18
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med (2015) 5.90
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes (2004) 4.81
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet (2005) 4.80
Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A (2007) 4.71
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Hypertrophy of the heart: a new therapeutic target? Circulation (2004) 4.45
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
MicroRNA-34a regulates cardiac ageing and function. Nature (2013) 4.03
Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA (2011) 3.90
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Investigation of the fine structure of European populations with applications to disease association studies. Eur J Hum Genet (2008) 3.65
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J (2006) 3.62
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol (2007) 3.56
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Case/pseudocontrol analysis in genetic association studies: A unified framework for detection of genotype and haplotype associations, gene-gene and gene-environment interactions, and parent-of-origin effects. Genet Epidemiol (2004) 3.39
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Association of warfarin dose with genes involved in its action and metabolism. Hum Genet (2006) 3.27
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem (2009) 3.24
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J (2006) 3.10
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
Geographical structure and differential natural selection among North European populations. Genome Res (2009) 3.03